Shares of Venus Remedies traded 2 percent higher on Wednesday after the pharma company received the marketing approval from Serbia for its drugs used in treatment of cancer.
"The company has secured marketing authorisation from Serbia for gemcitabine and docetaxel, widely used chemotherapy drugs beneficial in the treatment of various types of cancer. With this, Venus Remedies has now secured a total of 511 marketing approvals for its oncology products across 66 countries," the company said in a regulatory filing with the exchanges.
"We have more than 40 marketing authorisations in South Eastern Europe and Balkan region, including nine for oncology drugs. The marketing authorisation from Serbia is a significant milestone that will help improve access to affordable cancer drugs in the region," said Aditi Chaudhary, president of international business at Venus Remedies.
At 13:20 hours, shares of the company were trading at Rs 239.70 apiece, up by 6.50 apiece or 2.79 per cent.